NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) following repeated chemotherapy cycles: Results of a phase III trial.
Karin Jordan
Consultant or Advisory Role - Helsinn Therapeutics; Merck
Honoraria - Helsinn Therapeutics; Merck KGaA
Giorgia Rossi
Employment or Leadership Position - Helsinn Therapeutics
Giada Rizzi
Employment or Leadership Position - Helsinn Therapeutics
Marco Palmas
Employment or Leadership Position - Helsinn Therapeutics
Richard J. Gralla
Consultant or Advisory Role - Helsinn Therapeutics
Honoraria - Helsinn Therapeutics